Patients who will be getting cyclosporine, tacrolimus or other brokers to forestall graft-vs .-host ailment publish bone marrow transplant aren't suitable for this trial Elimusertib treatment displays that a progression-free survival benefit inside of a subset of preclinical pediatric stable tumors products when compared with SoC remedy. A, Illustration with https://joseonr999fqb1.wikissl.com/user